{"url":"https://lda.gov/api/v1/filings/de6ea471-2bb4-44d0-a42c-d12b00f99a28/","filing_uuid":"de6ea471-2bb4-44d0-a42c-d12b00f99a28","filing_type":"Q1","filing_type_display":"1st Quarter - Report","filing_year":2026,"filing_period":"first_quarter","filing_period_display":"1st Quarter (Jan 1 - Mar 31)","filing_document_url":"https://lda.gov/filings/public/filing/de6ea471-2bb4-44d0-a42c-d12b00f99a28/print/","filing_document_content_type":"text/html","income":null,"expenses":"1070000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jennie Skelton","dt_posted":"2026-04-20T13:30:23-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"Three Corporate Drive","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Lake Zurich","registrant_state":"IL","registrant_zip":"60047","registrant":{"id":401105533,"url":"https://lda.gov/api/v1/registrants/401105533/","house_registrant_id":null,"name":"FRESENIUS KABI USA LLC","description":"Generic and Biosimilar pharmaceutical manufacturer","address_1":"Three Corporate Drive","address_2":null,"address_3":null,"address_4":null,"city":"Lake Zurich","state":"IL","state_display":"Illinois","zip":"60047","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"CRAIG BURTON","contact_telephone":"+1 415-903-2800","dt_updated":"2026-07-27T17:51:39.556328-04:00"},"client":{"id":205669,"url":"https://lda.gov/api/v1/clients/205669/","client_id":12,"name":"FRESENIUS KABI USA LLC","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"IL","state_display":"Illinois","country":"US","country_display":"United States of America","ppb_state":"IL","ppb_state_display":"Illinois","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2020-08-12"},"lobbying_activities":[{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Medical Device Safety Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Federal Procurement Preferences for Domestic Medicines Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151684,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":107454,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":"CHRISTINE","last_name":"D'ORSIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152671,"prefix":null,"prefix_display":null,"first_name":"STU","nickname":null,"middle_name":null,"last_name":"EVENHAUGEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152962,"prefix":"mr","prefix_display":"MR.","first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"LEIBUNDGUTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MMM","general_issue_code_display":"Medicare/Medicaid","description":"CMS Preference for Domestic Essential Medicines Net Elective Cost Policy: PBM Reform Through Bid Transparency","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":107454,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":"CHRISTINE","last_name":"D'ORSIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":151684,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2296: National Defense Authorization Act (NDAA) for Fiscal Year 2026 Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR Medical Device Safety FDA Streamlining FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining FY27 National Defense Authorization Act - Domestic Production of Essential Medicines CMS Preference for Domestic Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform Net Elective Cost Policy: PBM Reform Through Bid Transparency Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC) Procurement","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":107454,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":"CHRISTINE","last_name":"D'ORSIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147340,"prefix":"mr","prefix_display":"MR.","first_name":"STEVEN","nickname":null,"middle_name":"CHASE","last_name":"WALKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152671,"prefix":null,"prefix_display":null,"first_name":"STU","nickname":null,"middle_name":null,"last_name":"EVENHAUGEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152962,"prefix":"mr","prefix_display":"MR.","first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"LEIBUNDGUTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":38,"name":"Labor, Dept of (DOL)"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"},{"id":42,"name":"Veterans Affairs, Dept of (VA)"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"MAN","general_issue_code_display":"Manufacturing","description":"Domestic Manufacturing CMS Preference for Domestic Essential Medicines Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151684,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152671,"prefix":null,"prefix_display":null,"first_name":"STU","nickname":null,"middle_name":null,"last_name":"EVENHAUGEN","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":25,"name":"Defense, Dept of (DOD)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"},{"id":12,"name":"White House Office"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"PTAB Proposed Rule - Restrict Use of IPR Patent Legislation Ancillary Product Patent Reform Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":107454,"prefix":null,"prefix_display":null,"first_name":"SARAH","nickname":null,"middle_name":"CHRISTINE","last_name":"D'ORSIE","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":147340,"prefix":"mr","prefix_display":"MR.","first_name":"STEVEN","nickname":null,"middle_name":"CHASE","last_name":"WALKER","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":24,"name":"Commerce, Dept of (DOC)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":113,"name":"Patent & Trademark Office (PTO)"},{"id":1,"name":"SENATE"},{"id":22,"name":"U.S. Trade Representative (USTR)"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Tax Incentives for Domestic Manufacturing Tax Credits for Domestic Manufacturing of Essential Medicines","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":151684,"prefix":null,"prefix_display":null,"first_name":"CRAIG","nickname":null,"middle_name":null,"last_name":"BURTON","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":152962,"prefix":"mr","prefix_display":"MR.","first_name":"CHRISTOPHER","nickname":null,"middle_name":null,"last_name":"LEIBUNDGUTH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}